Hepion Pharmaceuticals Inc (NASDAQ:HEPA) — Market Cap & Net Worth
Market Cap & Net Worth: Hepion Pharmaceuticals Inc (HEPA)
Hepion Pharmaceuticals Inc (NASDAQ:HEPA) has a market capitalization of $1.66 Million ($1.66 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30290 globally and #6160 in its home market, demonstrating a -8.09% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hepion Pharmaceuticals Inc's stock price $0.06 by its total outstanding shares 29119317 (29.12 Million). Also see Hepion Pharmaceuticals Inc asset portfolio for a full breakdown of the balance sheet.
Hepion Pharmaceuticals Inc Market Cap History: 2015 to 2026
Hepion Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $502.25 Billion to $1.82 Million (-69.44% CAGR). Also see Hepion Pharmaceuticals Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Hepion Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #887 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #2829 of 3165 |
Weight: Hepion Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Hepion Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hepion Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Hepion Pharmaceuticals Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of HEPA by Market Capitalization
Companies near Hepion Pharmaceuticals Inc in the global market cap rankings as of September 18, 2026. Review tangible equity quality of Hepion Pharmaceuticals Inc to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Hepion Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Hepion Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Hepion Pharmaceuticals Inc's market cap moved from $502.25 Billion to $ 1.82 Million, with a yearly change of -69.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.82 Million | -5.30% |
| 2025 | $1.92 Million | -85.96% |
| 2024 | $13.69 Million | -85.49% |
| 2023 | $94.35 Million | -46.05% |
| 2022 | $174.89 Million | -73.66% |
| 2021 | $663.92 Million | -47.95% |
| 2020 | $1.28 Billion | -59.14% |
| 2019 | $3.12 Billion | -72.85% |
| 2018 | $11.50 Billion | -90.21% |
| 2017 | $117.41 Billion | -70.00% |
| 2016 | $391.36 Billion | -22.08% |
| 2015 | $502.25 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Hepion Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.66 Million USD |
| MoneyControl | $1.66 Million USD |
| MarketWatch | $1.66 Million USD |
| marketcap.company | $1.66 Million USD |
| Reuters | $1.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hepion Pharmaceuticals Inc
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as … Read more